Eisai Co., Ltd.: Alzheimer Disease trials

The registry lists 44 Alzheimer Disease studies with Eisai Co., Ltd. as lead sponsor. 7 are open to participants now and 11 have results posted.

Phase 1 9Phase 2 7Phase 3 7Phase 4 8No phase 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Postmarketing Study of LEQEMBI in Participants With Alzheimer's DiseaseNot yet recruitingNCT07864623
• A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's DiseaseRecruitingNCT07821658
• A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)Not yet recruitingNCT07781345
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD)Not yet recruitingNCT07768592Phase 1
• A Post Authorization Registry Study of Participants Treated With LEQEMBIRecruitingNCT07762092
• A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's DiseaseRecruitingNCT06810960
• A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With LecanemabRecruitingNCT06322667
• A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's DiseaseCompletedNCT04971733Phase 1/2Results posted
• Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease DementiaCompletedNCT03001557Phase 2Results posted
• A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's DiseaseTerminatedNCT02956486Phase 3Results posted
• Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's DiseaseTerminatedNCT02322021Phase 2Results posted
• Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's DiseaseCompletedNCT02097056Phase 4Results posted
• A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's DiseaseCompletedNCT01767311Phase 2Results posted
• A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type DementiaCompletedNCT01276353Phase 2Results posted
• Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's DiseaseCompletedNCT00566501Phase 3Results posted
• Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's DiseaseCompletedNCT00478205Phase 3Results posted
• Neural Correlates In Mild Alzheimer's DiseaseCompletedNCT00477659Phase 4Results posted
• The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's DiseaseCompletedNCT00381381Phase 4Results posted
• A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's DiseaseActive, not recruitingNCT07723950
• A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's DiseaseActive, not recruitingNCT06602258Phase 2
• A Community-Based Screening Program to Identify Participants at High Risk for Amyloid PathologyActive, not recruitingNCT06043700
• A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseActive, not recruitingNCT03887455Phase 3
• A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy SubjectsCompletedNCT02859207Phase 1
• A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS)CompletedNCT02262975
• Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical PracticeCompletedNCT02162264
• Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's DiseaseCompletedNCT02162251
• A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease PatientsCompletedNCT02158910
• A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's DiseaseCompletedNCT02094729Phase 1
• An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on AbsorptionCompletedNCT01716897Phase 1
• Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)CompletedNCT01600859Phase 1
• Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's DiseaseCompletedNCT01539031Phase 3
• A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's DiseaseCompletedNCT01404169Phase 3
• Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly CohortCompletedNCT01294540Phase 1
• Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's DiseaseCompletedNCT01251718
• A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose StudyCompletedNCT01230853Phase 1
• A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy SubjectsCompletedNCT01221259Phase 1
• Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-CompletedNCT01129596
• Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's DiseaseWithdrawnNCT00711204Phase 4
• Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological MarkersCompletedNCT00403520Phase 4
• EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)CompletedNCT00230568Phase 4
• Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD PatientsTerminatedNCT00165750Phase 4
• Alzheimer's Disease Long-term Follow-up Study (ALF Study)CompletedNCT00165724Phase 4
• A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020CompletedNCT00165659Phase 2
• Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's DiseaseCompletedNCT00096473Phase 3